<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128622</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000437795</org_study_id>
    <secondary_id>DUMC-NCI-7042</secondary_id>
    <secondary_id>NCI-7042</secondary_id>
    <nct_id>NCT00128622</nct_id>
  </id_info>
  <brief_title>Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>A Phase I Study of Regulatory T Cell Depletion With Denileukin Diftitox Followed by Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox-Tricom in Patients With Advanced or Metastatic Malignancies Expressing CEA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Kim Lyerly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry&#xD;
      cancer-killing substances directly to the cancer cells. Vaccines made from a gene-modified&#xD;
      virus and a person's white blood cells may help the body build an effective immune response&#xD;
      to kill cancer cells. Giving denileukin diftitox together with vaccine therapy may kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of giving denileukin diftitox&#xD;
      together with vaccine therapy in treating patients with metastatic cancer that expresses&#xD;
      carcinoembryonic antigen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and feasibility of two different schedules of denileukin diftitox&#xD;
           followed by active immunotherapy comprising autologous dendritic cells infected with&#xD;
           recombinant fowlpox-CEA(6D)-TRICOM vaccine in patients with metastatic CEA-expressing&#xD;
           malignancies.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the immune response to this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, clinical response rate and/or time to progression in patients&#xD;
           with assessable disease treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients undergo leukapheresis for collection of peripheral blood mononuclear cells&#xD;
      (PBMCs). PBMCs are cultured with sargramostim (GM-CSF) and interleukin-4 for the production&#xD;
      of dendritic cells( DC). DC are mixed with recombinant fowlpox-TRICOM to produce the vaccine.&#xD;
      Patients are assigned to 1 of 2 cohorts according to timing of study enrollment.&#xD;
&#xD;
        -  Cohort 1: Patients receive denileukin diftitox IV over at least 15 minutes once in week&#xD;
           0 and vaccine therapy comprising autologous DC infected with recombinant fowlpox-CEA&#xD;
           (6D)-TRICOM vaccine intradermally and subcutaneously once in weeks 0 (beginning 4 days&#xD;
           after the denileukin diftitox infusion), 3, 6, and 9. If &lt; 2 of 6 patients experience&#xD;
           dose-limiting toxicity, a second cohort of patients is enrolled.&#xD;
&#xD;
        -  Cohort 2: Patients receive denileukin diftitox as in cohort 1 once in weeks 0, 3, 6, and&#xD;
           9 and vaccine as in cohort 1.&#xD;
&#xD;
      In both cohorts, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed annually for up to 15 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-12 patients (6 per cohort) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by rate of adverse events during study drug treatment</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of immune response as measured by ELISPot at week 10</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Denileukin Diftitox plus vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm Phase I safety study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denileukin diftitox</intervention_name>
    <arm_group_label>Denileukin Diftitox plus vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant fowlpox-CEA(6D)/TRICOM vaccine</intervention_name>
    <arm_group_label>Denileukin Diftitox plus vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
    <arm_group_label>Denileukin Diftitox plus vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignancy&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Tumor expresses carcinoembryonic antigen (CEA), as evidenced by any of the following:&#xD;
&#xD;
               -  At least 50% of tumor expresses CEA by immunohistochemistry (IHC) with ≥ a&#xD;
                  moderate intensity of staining&#xD;
&#xD;
               -  Peripheral blood CEA level &gt; 5.0 ng/mL&#xD;
&#xD;
               -  Tumor known to be universally CEA-positive (e.g., colon or rectal cancer)&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Received or refused prior therapy with a possible survival or palliative benefit AND&#xD;
             meets the following disease-specific criteria:&#xD;
&#xD;
               -  Patients with colorectal cancer must have experienced disease progression during&#xD;
                  ≥ 1 prior palliative chemotherapy regimen for metastatic disease comprising 1 of&#xD;
                  the following regimens:&#xD;
&#xD;
                    -  Fluorouracil or capecitabine AND oxaliplatin&#xD;
&#xD;
                    -  Fluorouracil or capecitabine AND irinotecan&#xD;
&#xD;
                    -  Chemotherapy in combination with bevacizumab&#xD;
&#xD;
               -  Patients with breast cancer must have experienced disease progression during ≥ 1&#xD;
                  prior palliative chemotherapy regimen for metastatic disease comprising 1 of the&#xD;
                  following regimens:&#xD;
&#xD;
                    -  Anthracycline- or taxane-based chemotherapy&#xD;
&#xD;
                    -  Chemotherapy AND trastuzumab (Herceptin®) (required for patients with tumors&#xD;
                       overexpressing HER2/neu (i.e., 3+ by IHC or positive by fluorescence in situ&#xD;
                       hybridization [FISH])&#xD;
&#xD;
               -  Patients with lung cancer must have experienced disease progression during ≥ 1&#xD;
                  prior palliative chemotherapy regimen for metastatic disease comprising 1 of the&#xD;
                  following regimens:&#xD;
&#xD;
                    -  Platinum-based (e.g., cisplatin or carboplatin) chemotherapy (for&#xD;
                       chemotherapy-naive patients only)&#xD;
&#xD;
                    -  Taxane-based (e.g., docetaxel or paclitaxel) chemotherapy OR vinorelbine&#xD;
                       (for patients who received prior chemotherapy)&#xD;
&#xD;
               -  Patients with pancreatic cancer must have experienced disease progression during&#xD;
                  prior chemotherapy, including gemcitabine&#xD;
&#xD;
               -  Patients with other malignancies must have experienced disease progression after&#xD;
                  prior first-line therapy that would confer a survival or palliative benefit, if&#xD;
                  such a therapy exists&#xD;
&#xD;
                    -  Patients who experienced disease progression during prior first-line&#xD;
                       palliative chemotherapy must be advised regarding second-line therapy before&#xD;
                       study enrollment&#xD;
&#xD;
          -  Previously resected brain metastases allowed provided there is no evidence of brain&#xD;
             metastasis within the past month by MRI or CT scan&#xD;
&#xD;
          -  No requirement for further systemic chemotherapy for ≥ 3 months&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL (transfusion or epoetin alfa allowed)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL (≤ 2.0 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  SGOT and SGPT &lt; 1.5 times upper limit of normal&#xD;
&#xD;
          -  Albumin ≥ 3.0 g/dL&#xD;
&#xD;
          -  No active acute or chronic viral hepatitis&#xD;
&#xD;
               -  Hepatitis B surface antigen negative&#xD;
&#xD;
               -  Hepatitis C negative&#xD;
&#xD;
          -  No other hepatic disease that would preclude study treatment&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  No active acute or chronic urinary tract infection&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III-IV cardiac disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of autoimmune disease*, including, but not limited to, the following:&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Ankylosing spondylitis&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
          -  No active cytomegalovirus (CMV) disease&#xD;
&#xD;
               -  Patients with CMV-seropositivity are eligible&#xD;
&#xD;
          -  No other active acute or chronic infection&#xD;
&#xD;
          -  No history of allergies to eggs or any component of the study vaccine, denileukin&#xD;
             diftitox, or diphtheria toxin NOTE: *Patients with a positive anti-nuclear antibody&#xD;
             (ANA) ≤ 1:256 with no other evidence of autoimmune disease are eligible&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No acute or chronic skin disorder that would preclude study treatment&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer, controlled&#xD;
             carcinoma in situ of the cervix, or controlled superficial bladder cancer&#xD;
&#xD;
          -  No psychological or medical impediment that would preclude study compliance&#xD;
&#xD;
          -  No other serious acute or chronic illness that would preclude study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior vaccine, dendritic cell, or CEA-targeted immunotherapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior and no other concurrent immunotherapy&#xD;
&#xD;
          -  Concurrent palliative single-agent trastuzumab for breast cancer allowed provided&#xD;
             patient has been on therapy for ≥ 3 months before study entry&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy&#xD;
&#xD;
          -  At least 6 weeks since prior steroid therapy except steroids used as premedication for&#xD;
             chemotherapy or contrast-enhanced studies&#xD;
&#xD;
          -  No concurrent steroids, including corticosteroids administered to manage toxic effects&#xD;
             from dendritic cell or denileukin diftitox administration&#xD;
&#xD;
          -  Concurrent palliative endocrine therapy for breast cancer allowed provided patient has&#xD;
             been on therapy for ≥ 3 months before study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs or procedures&#xD;
&#xD;
          -  At least 4 weeks since other prior therapy&#xD;
&#xD;
          -  No other concurrent immunosuppressive therapy (e.g., azathioprine or cyclosporine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Morse, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schonfeld K, Mahnke K, Schallenberg S, et al.: Treatment of melanoma bearing individuals with ONTAK® depletes regulatory T cells resulting in an augmented immune response following vaccination. [Abstract] J Invest Dermatol 126 (Suppl S3): A-594, s101, 2006.</citation>
  </reference>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>H. Kim Lyerly</investigator_full_name>
    <investigator_title>Professor, Gen &amp; Thor Surgery</investigator_title>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denileukin diftitox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

